Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences

Rhea-AI Summary

Fulcrum Therapeutics (NASDAQ: FULC) announced its participation in two upcoming investor conferences. The first is the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 2:35 p.m. PT, featuring a fireside chat. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 4:30 p.m. ET, also including a fireside chat. Interested investors can listen to live webcasts through the Investor Relations section of Fulcrum's website, with archived replays available for 30 days.

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:

• Credit Suisse 31^st Annual Healthcare Conference
  Tuesday, November 8, 2022 at 2:35 p.m. PT (Fireside Chat)
  

• Piper Sandler 34^th Annual Healthcare Conference
  Tuesday, November 29, 2022 at 4:30 p.m. ET (Fireside Chat)
  

Live audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 30 days.

About Fulcrum Therapeutics 
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter @FulcrumTx and LinkedIn.

Contacts:

Investors
Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200

Media
Dee Smith
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.
dsmith@fulcrumtx.com
202-746-1324

FAQ

What are the dates of the upcoming investor conferences for Fulcrum Therapeutics (FULC)?

Fulcrum Therapeutics will participate in two investor conferences: the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, and the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022.

How can I listen to Fulcrum Therapeutics' investor conference presentations?

Live audio webcasts of Fulcrum Therapeutics' presentations will be available on their Investor Relations website, with archived replays accessible for 30 days.

What is the focus of Fulcrum Therapeutics (FULC)?

Fulcrum Therapeutics is focused on improving the lives of patients with genetically defined rare diseases and has two lead programs in clinical development.

What are the names of Fulcrum Therapeutics' lead clinical programs?

Fulcrum Therapeutics' lead programs are losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.